Functional impairment, healthcare costs and the prevalence of institutionalisation in patients with Alzheimer's disease and other dementias

PharmacoEconomics

Volumn 24, Issue 3, 2006, Pages 265-280

  Hill, Jerrold ^a,e   Fillit, Howard ^b,c   Thomas, Simu K ^d   Chang, Sobin ^d  

^a Health Economics Research   (United States)

^b Alzheimers Drug Discovery Foundation   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e HEROE (Health Economics Research and Outcomes Evaluation)   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; TACRINE;

ALZHEIMER DISEASE; ARTICLE; DAILY LIFE ACTIVITY; DEMENTIA; FUNCTIONAL DISEASE; FUNCTIONAL STATUS; HEALTH CARE COST; HEALTH INSURANCE; HEALTH SERVICE; HUMAN; INSTITUTIONALIZATION; KATZ INDEX; LINEAR REGRESSION ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MEDICARE; PREVALENCE; PRIORITY JOURNAL;

AGED; ALZHEIMER DISEASE; COSTS AND COST ANALYSIS; DEMENTIA; FEMALE; HUMANS; INSTITUTIONALIZATION; MALE; MIDDLE AGED;

EID: 33644862199     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200624030-00006     Document Type: Article

References (34)

1. Baldereschi M, Di CA, Amaducci L. Epidemiology of dementias. Drugs Today 1998 Sep; 34 (9): 747-58
2. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders: consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA 1997 Oct; 278 (16): 1363-71
3. Mayeux R, Sano M. Treatment of Alzheimer's disease. N Engl J Med 1999 Nov; 341 (22): 1670-9
4. Meek PD, McKeithan K, Schumock GT. Economic considerations in Alzheimer's disease. Pharmacotherapy 1998 Mar; 18 (2 Pt 2): 68-73
5. Ernst RL, Hay JW. Economic research on Alzheimer disease: a review of the literature. Alzheimer Dis Assoc Disord 1997; 11 Suppl. 6: 135-45
6. Leon J, Chang-Kuo C, Neumann P. Alzheimer's disease care: costs and potential savings. Health Aff 1998; 17 (6): 206-16
7. Mittelman MS, Ferris SH, Shulman E, et al. An intervention that delays institutionalization of Alzheimer's disease patients: a treatment of spouse-caregivers. Gerontologist 1993; 33: 730-40
8. Rice DP, Fox PJ, Max W, et al. The economic burden of Alzheimer's disease care. Health Aff 1993; 12 (2): 164-76
9. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 1997; 11 Suppl. 2: S33-9
10. O'Brien JA, Caro JJ. Alzheimer's disease and other dementia in nursing homes: levels of management and cost. Int Psychogeriatr 2001; 13 (3): 347-58
11. Patterson MB, Mack JL, Neundorfer MM, et al. Assessment of functional ability in Alzheimer disease: a review and a preliminary report on the cleveland scale for activities of daily living. Alzheimer Dis Assoc Disord 1992; 6 (3): 145-63
12. DeJong R. Measurements of quality of life changes in patients with Alzheimer's disease. Clin Ther 1989; 11 (4): 545-54
13. Gauthier S, Lilienfeld S. Reminyl (galantamine) improves function and behaviour in Alzheimer's disease with cerebrovasculare components and in probable vascular dimentia. Poster presented at 10th Congress of the International Psychogeriatric Association; 2001 Sep 9-14; Nice (France)
14. Trinh N, Hoblyn J, Mohanty S, et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease. JAMA 2003; 289 (2): 210-6
15. Galasko D, Kershaw PR, Schneider L, et al. Galantamine maintains ability to perform activities of daily living in patients with Alzheimer's disease. J Am Geriatr Soc 2004 Jul; 52 (7): 1070-6
16. Farlow MR. Update on rivastigmine. Neurologist 2003 Sep; 9 (5): 230-4
17. Corey-Bloom J, Arnand R, Veach J, et al. A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease. Int J Geriatric Psychopharm 1998; 1: 55-65
18. Schneider LS, Anand R, Farlow MR. Systematic review of rivastigmine for patients with Alzheimer's disease. Int J Geriatric Psychopharm 1998; 1 Suppl. 1: S2-6
19. Rosler M, Anannd R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized control trial [published erratum appears in BMJ 2001 Jun 16; 322 (7300): 1456]. BMJ 2000; 318: 633-8
20. Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001 Aug; 57 (3): 489-95
21. Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002; 359: 1283-90
22. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004 Jan; 291 (3): 317-24
23. Hauber AD, Gnanasakthy A, Snyder EH, et al. Potential savings in the cost of caring for Alzheimer's disease. Pharmacoeconomics 2000; 17 (4): 351-60
24. Hill JW, Futterman R, Mastey V, et al. The effect of donepezil therapy on health costs in a medicare managed care plan. Manag Care Interface 2002; 15 (3): 63-70
25. Caro JJ, Migliaccio-Walle K, Ishak KJ, et al. Economic impact of galantamine in mild to moderate Alzheimer's disease. Poster presented at American Neurological Association; 2001 Sep 30-Oct 3; Chicago (IL)
26. The Centers of Medicare and Medicaid Services. The health and health care of medicare beneficiaries 2000 [online]. Available from URL: http://www.cms.hhs.gov/MCBS/PubHHC00.asp [Accessed 2004 May 20]
27. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998; 88: 1337-42
28. US Government Accounting Office. Alzheimer's disease: estimates of prevalence in the United States. Report to the Secretary of Health and Human Services. Washington, DC: US Government Accounting Office, 1998
29. Njegovan V, Hing MM, Mitchell S, et al. The hierarchy of functional loss associated with cognitive decline in older persons. J Gerontol A Biol Sci Med Sci 2001; 56A (10): M638-43
30. Ford GR, Haley WE, Thrower SL, et al. Utility of mini-mental state exam scores in predicting functional impairment among white and african american dementia patients. J Gerontol A Biol Sci Med Sci 1996; 51A (4): M185-8
31. Katz S, Ford AB, Moskowitz RW, et al. The index of ADL: a standardized measure of biological and psychosocial function. JAMA 1963; 185 (12): 914-9
32. Stephens S. A profile of Medicare. Chartbook. Washington, DC: Health Care Financing Administration, 1998
33. Hill JW, Futterman R, Duttagupta S, et al. Alzheimer's disease and related dementias increase costs of comorbidities in managed Medicare. Neurology 2002; 58: 62-70
34. Torian L, Davidson E, Fulop G, et al. The effect of dementia on acute care in a geriatric medical unit. Int Psychogeriatr 1992; 4: 231-9